Changes in classical and nonclassical HLA class I antigen and NK cell-activating ligand expression have been identified in malignant lesions.

A protective role against NK cells equipped of suitable inhibitory receptors has been proposed for nonclassical HLA-class I molecules including HLA-E and HLA-G.